{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:57:23Z","timestamp":1790913443130,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T00:00:00Z","timestamp":1779580800000},"content-version":"vor","delay-in-days":143,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000884","name":"Cancer Research Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000884","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101260","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:13:44Z","timestamp":1780013624000},"page":"101260","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["CRI-CCTG-0003\/IND.240 an immunotherapy platform study in platinum-resistant high grade serous ovarian cancer (IPROC): Sub-studies A and B: Durvalumab (D) + mecbotamab vedotin (BA3011) or ozuriftamab vedotin (BA3021)"],"prefix":"10.1016","volume":"48","author":[{"given":"Helen J.","family":"MacKay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna V.","family":"Tinker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4445-5539","authenticated-orcid":false,"given":"Brad H.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0094-0161","authenticated-orcid":false,"given":"Dmitriy","family":"Zamarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adekunle O.","family":"Odunsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4405-5890","authenticated-orcid":false,"given":"Stephanie","family":"Lheureux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5757-9787","authenticated-orcid":false,"given":"Susan","family":"Ellard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alannah","family":"Smrke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Olivier","family":"Gaudreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tess","family":"Faulkner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samik","family":"Upadhaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0388-8909","authenticated-orcid":false,"given":"Alicia","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Dancey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ctarc.2026.101260_bib0001","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s13045-025-01660-y","article-title":"Global status and attributable risk factors of breast, cervical, ovarian, and uterine cancers from 1990 to 2021","volume":"18","author":"Li","year":"2025","journal-title":"J. Hematol. Oncol."},{"issue":"10177","key":"10.1016\/j.ctarc.2026.101260_bib0002","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","article-title":"Epithelial ovarian cancer","volume":"393","author":"Lheureux","year":"2019","journal-title":"Lancet"},{"issue":"10538","key":"10.1016\/j.ctarc.2026.101260_bib0003","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S0140-6736(26)00602-1","article-title":"Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65\/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study","volume":"407","author":"Colombo","year":"2026","journal-title":"Lancet"},{"issue":"17_suppl","key":"10.1016\/j.ctarc.2026.101260_bib0004","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA5506","volume":"41","author":"Harter","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.ctarc.2026.101260_bib0005","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/S1470-2045(21)00342-9","article-title":"Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN ovarian 100): an open-label, randomised, phase 3 trial","volume":"22","author":"Monk","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2026.101260_bib0006","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ygyno.2019.04.053","article-title":"Avelumab alone or in combination with pegylated liposomal doxorubicin versus pegylated liposomal doxorubicin alone in platinum-resistant or refractory epithelial ovarian cancer: primary and biomarker analysis of the phase III JAVELIN ovarian 200 trial","volume":"154","author":"Pujade-Lauraine","year":"2019","journal-title":"Gynecol. Oncol."},{"issue":"7941","key":"10.1016\/j.ctarc.2026.101260_bib0007","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1038\/s41586-022-05496-1","article-title":"Ovarian cancer mutational processes drive site-specific immune evasion","volume":"612","author":"Vazquez-Garcia","year":"2022","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101260_bib0008","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ygyno.2011.09.039","article-title":"Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis","volume":"124","author":"Hwang","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ctarc.2026.101260_bib0009","article-title":"Current advances in PD-1\/PD-L1 blockade in recurrent epithelial ovarian cancer","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ctarc.2026.101260_bib0010","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1146\/annurev-immunol-070621-030155","article-title":"Resistance mechanisms to anti-PD cancer immunotherapy","volume":"40","author":"Vesely","year":"2022","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ctarc.2026.101260_bib0011","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1158\/1538-7445.AM2018-827","article-title":"Abstract 827: anti-tumor efficacy of BA3011, a novel conditionally active biologic (CAB) anti-AXL-ADC","volume":"78","author":"Sharp","year":"2018","journal-title":"Cancer Res."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101260_bib0012","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.anndiagpath.2013.01.005","article-title":"Axl and prostasin are biomarkers for prognosis of ovarian adenocarcinoma","volume":"17","author":"Chen","year":"2013","journal-title":"Ann. Diagn. Pathol."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101260_bib0013","first-page":"4155","article-title":"Computational and immunohistochemical analyses highlight AXL as a potential prognostic marker for ovarian cancer patients","volume":"36","author":"Lozneanu","year":"2016","journal-title":"Anticancer Res."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101260_bib0014","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ejca.2012.06.026","article-title":"Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer","volume":"49","author":"Marchini","year":"2013","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101260_bib0015","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101260_bib0016","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.tranon.2018.07.010","article-title":"Expression analysis of platinum sensitive and resistant epithelial ovarian cancer patient samples reveals new candidates for targeted therapies","volume":"11","author":"Veskimae","year":"2018","journal-title":"Transl. Oncol."},{"issue":"68","key":"10.1016\/j.ctarc.2026.101260_bib0017","doi-asserted-by":"crossref","first-page":"112727","DOI":"10.18632\/oncotarget.22559","article-title":"Silencing ROR1 and ROR2 inhibits invasion and adhesion in an organotypic model of ovarian cancer metastasis","volume":"8","author":"Henry","year":"2017","journal-title":"Oncotarget"},{"issue":"37","key":"10.1016\/j.ctarc.2026.101260_bib0018","doi-asserted-by":"crossref","first-page":"40310","DOI":"10.18632\/oncotarget.5643","article-title":"Targeting the ROR1 and ROR2 receptors in epithelial ovarian cancer inhibits cell migration and invasion","volume":"6","author":"Henry","year":"2015","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.ctarc.2026.101260_bib0019","doi-asserted-by":"crossref","DOI":"10.1038\/oncsis.2016.32","article-title":"Migration and invasion is inhibited by silencing ROR1 and ROR2 in chemoresistant ovarian cancer","volume":"5","author":"Henry","year":"2016","journal-title":"Oncogenesis"},{"issue":"3","key":"10.1016\/j.ctarc.2026.101260_bib0020","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","article-title":"Ovarian cancer development and metastasis","volume":"177","author":"Lengyel","year":"2010","journal-title":"Am. J. Pathol."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101260_bib0021","first-page":"15","article-title":"Chemo-immunotherapy: a new trend in cancer treatment","author":"Sordo-Bahamonde","year":"2023","journal-title":"Cancers. (Basel)"},{"issue":"16_suppl","key":"10.1016\/j.ctarc.2026.101260_bib0022","doi-asserted-by":"crossref","first-page":"6048","DOI":"10.1200\/JCO.2025.43.16_suppl.6048","article-title":"Phase 2 trial of ozuriftamab vedotin (BA3021), a conditionally binding ROR2-ADC, in patients with heavily pretreated squamous cell carcinoma of the head and neck","volume":"43","author":"Adkins","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101260_bib0023","article-title":"A phase 1\/2 dose-escalation and expansion study of a conditionally active anti-AXL humanized monoclonal antibody (BA3011) in patients with advanced solid tumors","volume":"36","author":"Ahnert","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2026.101260_bib0024","article-title":"523 median OS of 21.5 months among 44 patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma treated with mecbotamab vedotin, an AXL-targeting ADC","volume":"13","author":"Druta","year":"2025","journal-title":"J. ImmunOther Cancer"},{"issue":"16_suppl","key":"10.1016\/j.ctarc.2026.101260_bib0025","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1200\/JCO.2025.43.16_suppl.3077","article-title":"First report of ROR2 directed therapy with a conditionally active antibody drug conjugate in advanced melanoma","volume":"43","author":"Keeling","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101260_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2024.05.155","article-title":"PPD01.07 phase 2 trial of mecbotamab vedotin (BA3011), a CAB-AXL-ADC, alone or in combination with nivolumab in patients with non-squamous NSCLC","volume":"19","author":"Rotow","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ctarc.2026.101260_bib0027","article-title":"Interim safety and efficacy results from phase 1\/2 study of mecbotamab vedotin (BA3011), a CAB-AXL-ADC","author":"Wilky","year":"2021","journal-title":"Patients Adv. Sarcoma. Poster P154 present. at: Connect. Tissue Oncol. Soc. Annu. Meet. (Virtual)"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101260_bib0028","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"20","key":"10.1016\/j.ctarc.2026.101260_bib0029","doi-asserted-by":"crossref","first-page":"5037","DOI":"10.1158\/1078-0432.CCR-18-0784","article-title":"Consensus on molecular subtypes of high-grade serous ovarian carcinoma","volume":"24","author":"Chen","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.ctarc.2026.101260_bib0030","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0018064","article-title":"Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers","volume":"6","author":"Helland","year":"2011","journal-title":"PLoS. One"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101260_bib0031","first-page":"517","article-title":"Prognostically relevant gene signatures of high-grade serous ovarian carcinoma","volume":"123","author":"Verhaak","year":"2013","journal-title":"J. Clin. Invest."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101260_bib0032","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","article-title":"Determining cell type abundance and expression from bulk tissues with digital cytometry","volume":"37","author":"Newman","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ctarc.2026.101260_bib0033","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.687975","article-title":"IOBR: multi-Omics immuno-oncology biological research to decode tumor microenvironment and signatures","volume":"12","author":"Zeng","year":"2021","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.ctarc.2026.101260_bib0034","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1158\/2326-6066.CIR-18-0436","article-title":"Tumor microenvironment characterization in gastric cancer identifies prognostic and immunotherapeutically relevant gene signatures","volume":"7","author":"Zeng","year":"2019","journal-title":"Cancer Immunol. Res."},{"issue":"7693","key":"10.1016\/j.ctarc.2026.101260_bib0035","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ctarc.2026.101260_bib0036","first-page":"11","article-title":"Antibody-drug conjugates in breast cancer treatment: resistance mechanisms and the role of therapeutic sequencing","volume":"8","author":"Larose","year":"2025","journal-title":"Cancer Drug Resist."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101260_bib0037","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1038\/bjc.2017.367","article-title":"Antibody drug conjugates and bystander killing: is antigen-dependent internalisation required?","volume":"117","author":"Staudacher","year":"2017","journal-title":"Br. J. Cancer"},{"issue":"11, Supplement","key":"10.1016\/j.ctarc.2026.101260_bib0038","doi-asserted-by":"crossref","first-page":"S328","DOI":"10.1016\/j.jtho.2023.09.571","article-title":"P20.08-04 a phase 1\/2 dose escalation and dose expansion study of ozuriftamab vedotin (BA3021) alone and in combination with nivolumab","volume":"18","author":"Alexander","year":"2023","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ctarc.2026.101260_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.102443","article-title":"53O results from a phase II part I trial of mecbotamab vedotin (BA3011), a CAB-AXL-ADC, in patients with advanced refractory sarcoma","volume":"9","author":"Pollack","year":"2024","journal-title":"ESMo Open."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226001711?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226001711?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:47:35Z","timestamp":1790912855000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226001711"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":39,"alternative-id":["S2468294226001711"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101260","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CRI-CCTG-0003\/IND.240 an immunotherapy platform study in platinum-resistant high grade serous ovarian cancer (IPROC): Sub-studies A and B: Durvalumab (D) + mecbotamab vedotin (BA3011) or ozuriftamab vedotin (BA3021)","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101260","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101260"}}